Pooja Kinkhabwala, DO
Endocrinology, Diabetes & Metabolism · Merrillville, INNPI 1194104059
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Kyowa Kirin, Inc. at 47.8% of the total. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 954 payments — averaging $71.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$33K
- Abbott$9K
- Recordati_rare_diseases_inc.$7K
- Amgen$4K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- plus $12K from 54 others
What the payments were for
- Consulting fees$4,0756%
- Speaking & faculty fees$37,49555%
- Travel & lodging$6,1619%
- Food & beverage$20,38030%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,168 in reported general payments places this provider in the 90th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsturisaOsilodrostat Phosphate | 80 | $599,011 |
| JardianceEmpagliflozin | 192 | $262,638 |
| OzempicSemaglutide | 133 | $169,007 |
| MounjaroTirzepatide | 84 | $102,334 |
| TymlosAbaloparatide | 27 | $76,044 |
| TrulicityDulaglutide | 67 | $73,684 |
| FarxigaDapagliflozin Propanediol | 51 | $58,867 |
| Cinacalcet Hcl | 75 | $40,680 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 37 | $38,019 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $35,520 |
| VascepaIcosapent Ethyl | 44 | $34,433 |
| Gvoke Hypopen 2-PackGlucagon | 42 | $32,097 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $25,604 |
| KerendiaFinerenone | 14 | $20,087 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $18,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Recordati_rare_diseases_inc.Isturisa | $7,176 | $599,01180 claims |
| Boehringer IngelheimJardiance, Tradjenta | $673 | $278,058204 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,333 | $180,973185 claims |
| Novo NordiskOzempic, Novolog | $421 | $172,942155 claims |
| Radius Health, Inc.Tymlos | $498 | $76,04427 claims |
| AstraZenecaFarxiga | $2,300 | $58,86751 claims |
| BayerKerendia | $226 | $20,08714 claims |
| MerckJanuvia | $21 | $14,62212 claims |
| AbbVieSynthroid | $306 | $4,29057 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $120 | $2,748283 claims |
| Sanofi-aventis U.S. LLCLantus | $919 | $1,05213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Merrillville
- Nihad MuhrezMerrillville$271K
- Cydney Bullock-TiptonMerrillville$4K
- Richard LongleyMerrillville$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.